BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
EU delegation urges China to tighten export controls- 6 Vehicle Rental Administrations: Pick Your Ideal Ride
- Mexico says a third of 130,000 missing people might be alive, fueling criticism from families
- Don't miss the waxing moon swing by the Beehive star cluster March 27
- The Most Moving TED Talks You Want to Watch
- Extreme Manual for Purchasing Your Next Truck
- WHO issues guidance on GLP-1 drugs for obesity
- Judge approves Purdue Pharma’s new $7B opioid settlement with the Sacklers
- Santa's sleigh or the International Space Station? How to spot a bright Christmas flyby Dec. 24 and 25
